FC
SNDX icon

FORA Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

FORA Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,306
Closed -$29K – 1125
2021
Q1 		$29K Sell
1,306
-3,077
-70% -$69.5K 0.01% 638
2020
Q4 		$97K Buy
+4,383
New +$90.9K 0.01% 676
2020
Q3 		– Sell
-2,268
Closed -$34K – 955
2020
Q2 		$34K Buy
+2,268
New +$34.5K 0.01% 726

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FORA Capital's SNDX Position: Q2 2021 in Review

FORA Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 1,306 shares — an estimated $29K sold.

FORA Capital first reported a position in SNDX in Q2 2020 and held it in 3 quarters. The position peaked at $97K in Q4 2020. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • FORA Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • FORA Capital sold 1,306 Syndax Pharmaceuticals shares in Q2 2021, an estimated $29K.
  • FORA Capital first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • FORA Capital's Syndax Pharmaceuticals position peaked at $97K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.